# 10x Genomics, Inc.: financial statements, quarterly

TXG · Nasdaq · CIK 1770787 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/txg.md) · [Financials](/companies/txg/financials.md) · [Filings](/companies/txg/filings.md) · [Insiders](/companies/txg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/txg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [154](/filings/0001770787-24-000073.md) | [184 d](/filings/0001628280-26-007822.md) | [141](/filings/0001770787-25-000032.md) | [153](/filings/0001770787-25-000051.md) | [152](/filings/0001628280-25-050332.md) | [165 d](/filings/0001628280-26-007822.md) | [155](/filings/0001628280-26-032388.md) | [173](/filings/0001628280-26-054491.md) | [149](/filings/0001628280-25-050332.md) | [166 d](/filings/0001628280-26-007822.md) | [151](/filings/0001628280-26-032388.md) | [151](/filings/0001628280-26-054491.md) |
| Cost of revenue | $m | [58.1](/filings/0001770787-24-000073.md) | [68.2 d](/filings/0001628280-26-007822.md) | [48.1](/filings/0001770787-25-000032.md) | [48.9](/filings/0001770787-25-000051.md) | [45.3](/filings/0001628280-25-050332.md) | [54.1 d](/filings/0001628280-26-007822.md) | [49.4](/filings/0001628280-26-032388.md) | [47.8](/filings/0001628280-26-054491.md) | [48.7](/filings/0001628280-25-050332.md) | [53.0 d](/filings/0001628280-26-007822.md) | [44.7](/filings/0001628280-26-032388.md) | [38.5](/filings/0001628280-26-054491.md) |
| Gross profit | $m | [95.5](/filings/0001770787-24-000073.md) | [116 d](/filings/0001628280-26-007822.md) | [92.9](/filings/0001770787-25-000032.md) | [104](/filings/0001770787-25-000051.md) | [106](/filings/0001628280-25-050332.md) | [111 d](/filings/0001628280-26-007822.md) | [105](/filings/0001628280-26-032388.md) | [125](/filings/0001628280-26-054491.md) | [100](/filings/0001628280-25-050332.md) | [113 d](/filings/0001628280-26-007822.md) | [106](/filings/0001628280-26-032388.md) | [112](/filings/0001628280-26-054491.md) |
| Selling, general and administrative | $m | [82.4](/filings/0001770787-24-000073.md) | [86.1 d](/filings/0001628280-26-007822.md) | [85.8](/filings/0001770787-25-000032.md) | [83.0](/filings/0001770787-25-000051.md) | [81.7](/filings/0001628280-25-050332.md) | [93.8 d](/filings/0001628280-26-007822.md) | [89.7](/filings/0001628280-26-032388.md) | [74.4](/filings/0001628280-26-054491.md) | [75.4](/filings/0001628280-25-050332.md) | [76.6 d](/filings/0001628280-26-007822.md) | [66.4](/filings/0001628280-26-032388.md) | [78.7](/filings/0001628280-26-054491.md) |
| Operating income | $m | [(94.8)](/filings/0001770787-24-000073.md) | [(55.2) d](/filings/0001628280-26-007822.md) | [(61.5)](/filings/0001770787-25-000032.md) | [(41.7)](/filings/0001770787-25-000051.md) | [(41.5)](/filings/0001628280-25-050332.md) | [(49.8) d](/filings/0001628280-26-007822.md) | [(39.3)](/filings/0001628280-26-032388.md) | [30.1](/filings/0001628280-26-054491.md) | [(32.2)](/filings/0001628280-25-050332.md) | [(19.5) d](/filings/0001628280-26-007822.md) | [(17.0)](/filings/0001628280-26-032388.md) | [(19.6)](/filings/0001628280-26-054491.md) |
| Interest expense | $m | [0.0](/filings/0001770787-23-000053.md) | [0.0 d](/filings/0001770787-24-000017.md) | [0.0](/filings/0001770787-24-000036.md) | [0.0](/filings/0001770787-25-000051.md) | [0.0](/filings/0001628280-25-050332.md) | [0.0 d](/filings/0001628280-26-007822.md) | [0.0](/filings/0001770787-25-000032.md) | [0.0](/filings/0001628280-26-054491.md) | [(0.0)](/filings/0001628280-25-050332.md) | [0.0 d](/filings/0001628280-26-007822.md) | not reported | [0.0](/filings/0001628280-26-054491.md) |
| Income tax | $m | [1.2](/filings/0001770787-24-000073.md) | [2.4 d](/filings/0001628280-26-007822.md) | [2.1](/filings/0001770787-25-000032.md) | [0.8](/filings/0001770787-25-000051.md) | [1.3](/filings/0001628280-25-050332.md) | [0.6 d](/filings/0001628280-26-007822.md) | [0.9](/filings/0001628280-26-032388.md) | [2.5](/filings/0001628280-26-054491.md) | [(0.7)](/filings/0001628280-25-050332.md) | [1.1 d](/filings/0001628280-26-007822.md) | [0.6](/filings/0001628280-26-032388.md) | [(0.7)](/filings/0001628280-26-054491.md) |
| Net income | $m | [(93.0)](/filings/0001770787-24-000073.md) | [(49.0) d](/filings/0001628280-26-007822.md) | [(59.9)](/filings/0001628280-25-050332.md) | [(37.9)](/filings/0001628280-25-050332.md) | [(35.8)](/filings/0001628280-25-050332.md) | [(49.0) d](/filings/0001628280-26-007822.md) | [(34.4)](/filings/0001628280-26-054491.md) | [34.5](/filings/0001628280-26-054491.md) | [(27.5)](/filings/0001628280-25-050332.md) | [(16.3) d](/filings/0001628280-26-007822.md) | [(13.5)](/filings/0001628280-26-054491.md) | [(17.9)](/filings/0001628280-26-054491.md) |
| Diluted EPS | $ per share | [(0.79)](/filings/0001770787-24-000073.md) | not reported | [(0.50)](/filings/0001770787-25-000032.md) | [(0.32)](/filings/0001770787-25-000051.md) | [(0.30)](/filings/0001628280-25-050332.md) | not reported | [(0.28)](/filings/0001628280-26-032388.md) | [0.28](/filings/0001628280-26-054491.md) | [(0.22)](/filings/0001628280-25-050332.md) | not reported | [(0.10)](/filings/0001628280-26-032388.md) | [(0.14)](/filings/0001628280-26-054491.md) |
| Basic EPS | $ per share | [(0.79)](/filings/0001770787-24-000073.md) | not reported | [(0.50)](/filings/0001770787-25-000032.md) | [(0.32)](/filings/0001770787-25-000051.md) | [(0.30)](/filings/0001628280-25-050332.md) | not reported | [(0.28)](/filings/0001628280-26-032388.md) | [0.28](/filings/0001628280-26-054491.md) | [(0.22)](/filings/0001628280-25-050332.md) | not reported | [(0.10)](/filings/0001628280-26-032388.md) | [(0.14)](/filings/0001628280-26-054491.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [359](/filings/0001770787-25-000013.md) | not reported | not reported | not reported | [344](/filings/0001770787-25-000013.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [562](/filings/0001770787-23-000053.md) | [596](/filings/0001770787-25-000013.md) | [567](/filings/0001770787-24-000036.md) | [579](/filings/0001770787-24-000060.md) | [594](/filings/0001770787-24-000073.md) | [584](/filings/0001628280-26-007822.md) | [580](/filings/0001770787-25-000032.md) | [656](/filings/0001770787-25-000051.md) | [660](/filings/0001628280-25-050332.md) | [684](/filings/0001628280-26-054491.md) | [670](/filings/0001628280-26-032388.md) | [675](/filings/0001628280-26-054491.md) |
| Total assets | $m | [949](/filings/0001770787-23-000053.md) | [965](/filings/0001770787-25-000013.md) | [923](/filings/0001770787-24-000036.md) | [930](/filings/0001770787-24-000060.md) | [938](/filings/0001770787-24-000073.md) | [919](/filings/0001628280-26-007822.md) | [903](/filings/0001770787-25-000032.md) | [980](/filings/0001770787-25-000051.md) | [1,027](/filings/0001628280-25-050332.md) | [1,041](/filings/0001628280-26-054491.md) | [1,016](/filings/0001628280-26-032388.md) | [1,030](/filings/0001628280-26-054491.md) |
| Current liabilities | $m | [105](/filings/0001770787-23-000053.md) | [127](/filings/0001770787-25-000013.md) | [109](/filings/0001770787-24-000036.md) | [111](/filings/0001770787-24-000060.md) | [121](/filings/0001770787-24-000073.md) | [118](/filings/0001628280-26-007822.md) | [108](/filings/0001770787-25-000032.md) | [112](/filings/0001770787-25-000051.md) | [147](/filings/0001628280-25-050332.md) | [153](/filings/0001628280-26-054491.md) | [114](/filings/0001628280-26-032388.md) | [119](/filings/0001628280-26-054491.md) |
| Total liabilities | $m | [203](/filings/0001770787-23-000053.md) | [224](/filings/0001770787-25-000013.md) | [204](/filings/0001770787-24-000036.md) | [206](/filings/0001770787-24-000060.md) | [215](/filings/0001770787-24-000073.md) | [209](/filings/0001628280-26-007822.md) | [196](/filings/0001770787-25-000032.md) | [207](/filings/0001770787-25-000051.md) | [242](/filings/0001628280-25-050332.md) | [245](/filings/0001628280-26-054491.md) | [201](/filings/0001628280-26-032388.md) | [205](/filings/0001628280-26-054491.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [745](/filings/0001770787-24-000073.md) | [741](/filings/0001628280-26-007822.md) | [719](/filings/0001628280-25-050332.md) | [724](/filings/0001628280-25-050332.md) | [723](/filings/0001628280-25-050332.md) | [710](/filings/0001628280-26-054491.md) | [707](/filings/0001628280-26-054491.md) | [773](/filings/0001628280-26-054491.md) | [785](/filings/0001628280-25-050332.md) | [796](/filings/0001628280-26-054491.md) | [814](/filings/0001628280-26-054491.md) | [826](/filings/0001628280-26-054491.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(25.3) d](/filings/0001770787-24-000073.md) | [25.8 d](/filings/0001628280-26-007822.md) | [(15.7)](/filings/0001770787-25-000032.md) | [7.5 d](/filings/0001770787-25-000051.md) | [21.6 d](/filings/0001628280-25-050332.md) | [(6.7) d](/filings/0001628280-26-007822.md) | [34.4](/filings/0001628280-26-032388.md) | [17.7 d](/filings/0001628280-26-054491.md) | [43.2 d](/filings/0001628280-25-050332.md) | [40.8 d](/filings/0001628280-26-007822.md) | [26.1](/filings/0001628280-26-032388.md) | [17.0 d](/filings/0001628280-26-054491.md) |
| Capital expenditure | $m | [15.2 d](/filings/0001770787-24-000073.md) | [3.5 d](/filings/0001628280-26-007822.md) | [2.9](/filings/0001770787-25-000032.md) | [2.9 d](/filings/0001770787-25-000051.md) | [3.9 d](/filings/0001628280-25-050332.md) | [2.7 d](/filings/0001628280-26-007822.md) | [1.9](/filings/0001628280-26-032388.md) | [1.6 d](/filings/0001628280-26-054491.md) | [0.7 d](/filings/0001628280-25-050332.md) | [1.8 d](/filings/0001628280-26-007822.md) | [1.6](/filings/0001628280-26-032388.md) | [1.6 d](/filings/0001628280-26-054491.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [114](/filings/0001770787-23-000053.md) | [116](/filings/0001770787-24-000036.md) | [117](/filings/0001770787-24-000060.md) | [118](/filings/0001770787-24-000073.md) | [119](/filings/0001770787-25-000032.md) | [120](/filings/0001770787-25-000051.md) | [121](/filings/0001628280-25-050332.md) | [123](/filings/0001628280-26-032388.md) | [125](/filings/0001628280-26-054491.md) | [126](/filings/0001628280-25-050332.md) | [128](/filings/0001628280-26-032388.md) | [130](/filings/0001628280-26-054491.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.